Jane Street Group, LLC Krystal Biotech, Inc. Call Options Transaction History

Jane Street Group, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $6.9 Million - $8.44 Million	39,500 New	39,500 $7.18 Million
Q1 2022 May 17, 2022	BUY	$51.99 - $72.11 $181,965 - $252,385	3,500 Added 27.78%	16,100 $1.07 Million
Q4 2021 Feb 15, 2022	SELL	$39.81 - $88.24 $867,858 - $1.92 Million	-21,800 Reduced 63.37%	12,600 $881,000
Q3 2021 Nov 16, 2021	BUY	$52.01 - $71.77 $1.79 Million - $2.47 Million	34,400 New	34,400 $1.8 Million
Q3 2020 Nov 17, 2020	SELL	$37.76 - $48.49 $373,824 - $480,051	-9,900 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$37.03 - $60.0 $366,597 - $594,000	9,900 New	9,900 $410,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.38B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.